{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:27:13Z","timestamp":1788460033061,"version":"build-2803163510"},"reference-count":239,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune rheumatic diseases (ARDs) are a diverse group of chronic disorders characterized by immune dysregulation and multi-organ inflammation. B cell receptor (BCR) signaling emerges as a shared, yet heterogeneously regulated, pathogenic axis across these diseases. This dysregulation drives B cell activation, autoantibody production, and ultimately tissue damage. Recent research highlights its involvement in both common and disease-specific mechanisms, which helps explain the wide variation in clinical features and therapeutic responses across ARDs. This review summarizes current evidence establishing BCR signaling as a central regulatory and therapeutic target in rheumatoid arthritis, systemic lupus erythematosus, Sj\u00f6gren\u2019s syndrome, IgG4-related disease, and ANCA-associated vasculitis. It integrates mechanistic insights with recent clinical trial data on BCR signaling-targeted therapies, discussing factors that may contribute to variability in therapeutic responses and treatment limitations. Finally, we outline current challenges and future directions for precision medicine in ARDs, with a focus on biomarker-guided strategies and innovative combination therapies to improve patient outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1750557","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:00:00Z","timestamp":1772607600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting"],"prefix":"10.3389","volume":"17","author":[{"given":"Yin","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Guizhou Children\u2019s Hospital","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Guizhou Children\u2019s Hospital","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Guizhou Children\u2019s Hospital","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fucai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Guizhou Children\u2019s Hospital","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Guizhou Children\u2019s Hospital","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Dai","sequence":"additional","affiliation":[{"name":"Zhanjiang Institute of Clinical Medicine, Central People\u2019s Hospital of Zhanjiang","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufen","family":"Wang","sequence":"additional","affiliation":[{"name":"Zhanjiang Institute of Clinical Medicine, Central People\u2019s Hospital of Zhanjiang","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Guizhou Children\u2019s Hospital","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Guizhou Children\u2019s Hospital","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Guizhou Children\u2019s Hospital","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuochen","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Guizhou Children\u2019s Hospital","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100129","article-title":"Autoimmune rheumatic diseases: One or many diseases","volume":"4","author":"Moutsopoulos","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3899\/jrheum.110901","article-title":"Socioeconomic burden of immune-mediated inflammatory diseases--focusing on work productivity and disability","volume":"88","author":"Jacobs","year":"2011","journal-title":"J Rheumatol Suppl"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00095","article-title":"Toll-like receptor signaling drives btk-mediated autoimmune disease","volume":"10","author":"Rip","year":"2019","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103326","article-title":"Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103407","article-title":"A global assessment of incidence trends of autoimmune diseases from 1990 to 2019 and predicted changes to 2040","volume":"22","author":"Li","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e005227","DOI":"10.1136\/rmdopen-2024-005227","article-title":"Rising incidence of systemic autoimmune inflammatory rheumatic diseases during the COVID-19 pandemic: a geographical cohort study","volume":"11","author":"De Lorenzis","year":"2025","journal-title":"RMD Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.04.009","article-title":"Spatiotemporal distributions and regional disparities of rheumatoid arthritis in 953 global to local locations, 1980-2040, with deep learning-empowered forecasts and evaluation of interventional policies\u2019 benefits","volume":"84","author":"Jin","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"i24","DOI":"10.1093\/rheumatology\/keaf008","article-title":"IgG4-related disease: lessons from the first 20 years","volume":"64","author":"Stone","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0211-0","article-title":"B cell checkpoints in autoimmune rheumatic diseases","volume":"15","author":"Rubin","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051190","article-title":"B cell activation and escape of tolerance checkpoints: recent insights from studying autoreactive B cells","volume":"10","author":"Bonasia","year":"2021","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8609-4","article-title":"Intracellular B lymphocyte signalling and the regulation of humoral immunity and autoimmunity","volume":"53","author":"Taher","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05419-x","article-title":"Coexistence of IgG4-related disease and ANCA-associated vasculitis: case report and review of the literature","volume":"44","author":"Korkmaz","year":"2024","journal-title":"Rheumatol Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2019.09.004","article-title":"B cell targeted therapies in autoimmune disease","volume":"61","author":"Barnas","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103133","article-title":"Targeting NF-\u03baB signaling in B cells as a potential new treatment modality for ANCA-associated vasculitis","volume":"142","author":"Merino-Vico","year":"2024","journal-title":"J Autoimmun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e14582","DOI":"10.1111\/cbdd.14582","article-title":"Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis","volume":"104","author":"Paliwal","year":"2024","journal-title":"Chem Biol Drug Des"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1502712","article-title":"CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases","volume":"15","author":"Rangel-Pel\u00e1ez","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158656","article-title":"Activation markers on B and T cells and immune checkpoints in autoimmune rheumatic diseases","volume":"23","author":"Gerasimova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-024-09003-4","article-title":"Methylation of T and B lymphocytes in autoimmune rheumatic diseases","volume":"66","author":"Deng","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010010","article-title":"B-cell receptor signaling and beyond: the role of ig\u03b1 (CD79a)\/ig\u03b2 (CD79b) in normal and Malignant B cells","volume":"25","author":"Tkachenko","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05412-7","article-title":"Structural principles of B cell antigen receptor assembly","volume":"612","author":"Dong","year":"2022","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01327-1","article-title":"Immunoglobulin divalence promotes B-cell antigen receptor cluster scale-dependent functions","volume":"22","author":"Yilmaz","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri2853","article-title":"The tipping points in the initiation of B cell signalling: how small changes make big differences","volume":"10","author":"Pierce","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bpj.2013.10.043","article-title":"Ligand mobility regulates B cell receptor clustering and signaling activation","volume":"106","author":"Ketchum","year":"2014","journal-title":"Biophys J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-024-01073-x","article-title":"Towards a unifying model for B-cell receptor triggering","volume":"25","author":"Degn","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80591-9","article-title":"BLNK: a central linker protein in B cell activation","volume":"9","author":"Fu","year":"1998","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000026","article-title":"The regulators of BCR signaling during B cell activation","volume":"1","author":"Wen","year":"2019","journal-title":"Blood Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100905","article-title":"The role of PLC\u03b32 in immunological disorders, cancer, and neurodegeneration","volume":"297","author":"Jackson","year":"2021","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2023.119475","article-title":"Phosphatidylinositol 4, 5-bisphosphate and calcium at ER-PM junctions - Complex interplay of simple messengers","volume":"1870","author":"Ivanova","year":"2023","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113463","article-title":"Effect of leech-centipede medicine on improving erectile function in DIED rats via PKC signalling pathway-related molecules","volume":"267","author":"Wang","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1593338","article-title":"B cell development: transcriptional regulation and immunological mechanisms in homeostasis","volume":"16","author":"G\u00f3mez-Manr\u00edquez","year":"2025","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104133","article-title":"The LUBAC participates in lysophosphatidic acid-induced NF-\u03baB activation","volume":"353","author":"Douanne","year":"2020","journal-title":"Cell Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1155421","article-title":"B cell activation via immunometabolism in systemic lupus erythematosus","volume":"14","author":"Iwata","year":"2023","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00497","article-title":"LAMTOR2 (p14) controls B cell differentiation by orchestrating endosomal BCR trafficking","volume":"10","author":"\u0141yszkiewicz","year":"2019","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150537","article-title":"Continuous inhibitory signaling by both SHP-1 and SHIP-1 pathways is required to maintain unresponsiveness of anergic B cells","volume":"213","author":"Getahun","year":"2016","journal-title":"J Exp Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"101116","DOI":"10.1016\/j.jbior.2025.101116","article-title":"CD19 structure, expression, and signaling: From basic mechanisms to therapeutic targeting","volume":"99","author":"Schurmans","year":"2025","journal-title":"Adv Biol Regul"},{"key":"B40","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41419-024-07180-w","article-title":"DOCK8 gene mutation alters cell subsets, BCR signaling, and cell metabolism in B cells","volume":"15","author":"Gu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jaci.2020.09.033","article-title":"STAT3 couples with 14-3-3\u03c3 to regulate BCR signaling, B-cell differentiation, and IgE production","volume":"147","author":"Du","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114454","article-title":"Notch2 signaling governs activated B cells to form memory B cells","volume":"43","author":"Xu","year":"2024","journal-title":"Cell Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"eaaw0315","DOI":"10.1126\/sciadv.aaw0315","article-title":"Fc receptor-like 1 intrinsically recruits c-Abl to enhance B cell activation and function","volume":"5","author":"Zhao","year":"2019","journal-title":"Sci Adv"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6971","DOI":"10.1038\/s41467-024-51166-3","article-title":"TFEB activation hallmarks antigenic experience of B lymphocytes and directs germinal center fate decisions","volume":"15","author":"M\u00fcnchhalfen","year":"2024","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s44320-025-00124-2","article-title":"Synergy and antagonism in the integration of BCR and CD40 signals that control B-cell population expansion","volume":"21","author":"Huang","year":"2025","journal-title":"Mol Syst Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0902454","article-title":"The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM- and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA","volume":"73","author":"Huang","year":"2003","journal-title":"J Leukoc Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41419-025-07352-2","article-title":"MAPK4 inhibits the early aberrant activation of B cells in rheumatoid arthritis by promoting the IRF4-SHIP1 signaling pathway","volume":"16","author":"Huang","year":"2025","journal-title":"Cell Death Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1038\/s41467-018-05770-9","article-title":"Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycans","volume":"9","author":"Giovannone","year":"2018","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41467-020-14335-8","article-title":"WASP family proteins regulate the mobility of the B cell receptor during signaling activation","volume":"11","author":"Rey-Suarez","year":"2020","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e149376","DOI":"10.1172\/jci.insight.149376","article-title":"ARPC1B binds WASP to control actin polymerization and curtail tonic signaling in B cells","volume":"6","author":"Leung","year":"2021","journal-title":"JCI Insight"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213391","article-title":"Aberrant B cell signaling in autoimmune diseases","volume":"11","author":"Corneth","year":"2022","journal-title":"Cells"},{"key":"B53","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41467-023-36672-0","article-title":"Antigen footprint governs activation of the B cell receptor","volume":"14","author":"Ferapontov","year":"2023","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103851","article-title":"Autoreactive B cells in autoimmune diseases: Mechanisms, functions and clinical implications","volume":"24","author":"Collet","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-397919","article-title":"Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice","volume":"119","author":"Kil","year":"2012","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"eadt8199","DOI":"10.1126\/sciadv.adt8199","article-title":"Critical roles of chronic BCR signaling in the differentiation of anergic B cells into age-associated B cells in aging and autoimmunity","volume":"11","author":"Imabayashi","year":"2025","journal-title":"Sci Adv"},{"key":"B57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12016-025-09021-w","article-title":"Age-associated B cells in autoimmune diseases: pathogenesis and clinical implications","volume":"68","author":"Xie","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/critrevimmunol.v30.i1.10","article-title":"Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses","volume":"30","author":"Pone","year":"2010","journal-title":"Crit Rev Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1538555","article-title":"The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e70004","DOI":"10.1111\/imr.70004","article-title":"Signaling activation and modulation in extrafollicular B cell responses","volume":"330","author":"Staniek","year":"2025","journal-title":"Immunol Rev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1620073","article-title":"Common pathological mechanisms and therapeutic strategies in primary Sjogren\u2019s syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy","volume":"16","author":"Ye","year":"2025","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002539","article-title":"Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sj\u00f6gren\u2019s syndrome","volume":"136","author":"Li","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer","year":"2020","journal-title":"J Autoimmun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41584-024-01096-7","article-title":"Low-frequency and rare genetic variants associated with rheumatoid arthritis risk","volume":"20","author":"Kronzer","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1556971","article-title":"From genetic variants to therapeutic targets: insights into understanding rheumatoid arthritis","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/joim.70040","article-title":"Genetic risk factors and clinical manifestations of systemic lupus erythematosus: Large-scale analysis of genetic predisposition and disease subtypes","volume":"299","author":"Reid","year":"2026","journal-title":"J Intern Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103738","article-title":"Immunometabolic shifts in autoimmune disease: Mechanisms and pathophysiological implications","volume":"24","author":"Chen","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02102-0","article-title":"B cell immunometabolism in health and disease","volume":"26","author":"Martinis","year":"2025","journal-title":"Nat Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1713148","article-title":"Immunocyte lipid metabolic reprogramming: a novel pathway for targeted intervention in autoimmune diseases","volume":"16","author":"Cui","year":"2025","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e11945","DOI":"10.1002\/advs.202511945","article-title":"Synovium-on-A-chip: simulating the microenvironment of the rheumatoid arthritis synovium via multicell interactions to target fibroblast-like synoviocytes","volume":"12","author":"Diao","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2025.06.008","article-title":"Cellular interactions in maintaining an inflammatory microenvironment in rheumatoid arthritis","volume":"184","author":"Ganeshalingam","year":"2025","journal-title":"Mol Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1556359","article-title":"Resolution of inflammation during rheumatoid arthritis","volume":"13","author":"Ye","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103168","article-title":"Aberrant B cell receptor signaling in circulating na\u00efve and IgA(+) memory B cells from newly-diagnosed autoantibody-positive rheumatoid arthritis patients","volume":"143","author":"Neys","year":"2024","journal-title":"J Autoimmun"},{"key":"B74","doi-asserted-by":"publisher","first-page":"eaaz5327","DOI":"10.1126\/scitranslmed.aaz5327","article-title":"Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis","volume":"12","author":"Kristyanto","year":"2020","journal-title":"Sci Transl Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e202451361","DOI":"10.1002\/eji.202451361","article-title":"Increased phosphorylation of intracellular signaling molecules indicates continuous activation of human autoreactive B-cells","volume":"55","author":"Kroos","year":"2025","journal-title":"Eur J Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750753","article-title":"B cells in rheumatoid arthritis:Pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.613","article-title":"Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis","volume":"182","author":"Nowell","year":"2009","journal-title":"J Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4110\/in.2014.14.1.21","article-title":"Insights into the role of follicular helper T cells in autoimmunity","volume":"14","author":"Park","year":"2014","journal-title":"Immune Netw"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-019-01777-x","article-title":"Activation of NF-\u03baB in B cell receptor signaling through Bruton\u2019s tyrosine kinase-dependent phosphorylation of I\u03baB-\u03b1","volume":"97","author":"Pontoriero","year":"2019","journal-title":"J Mol Med (Berl)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048968","article-title":"Bruton\u2019s tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice","volume":"51","author":"Rip","year":"2021","journal-title":"Eur J Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e70207","DOI":"10.1002\/mco2.70207","article-title":"A novel dual bruton\u2019s tyrosine kinase\/janus kinase 3 inhibitor wj1113 and its therapeutic effects on rheumatoid arthritis","volume":"6","author":"Zhang","year":"2025","journal-title":"MedComm (2020)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00228","article-title":"Akt and mTOR in B cell activation and differentiation","volume":"3","author":"Limon","year":"2012","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","article-title":"Signaling pathways in rheumatoid arthritis: implications for targeted therapy","volume":"8","author":"Ding","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e0147788","DOI":"10.1371\/journal.pone.0147788","article-title":"The elevated secreted immunoglobulin D enhanced the activation of peripheral blood mononuclear cells in rheumatoid arthritis","volume":"11","author":"Wu","year":"2016","journal-title":"PloS One"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.24","article-title":"Altered B cell signalling in autoimmunity","volume":"17","author":"Rawlings","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615673","article-title":"Recent advances in lupus B cell biology: PI3K, IFN\u03b3, and chromatin","volume":"11","author":"Bacalao","year":"2020","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103648","article-title":"Immunopathogenesis of systemic lupus erythematosus: An update","volume":"23","author":"Arnaud","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01179-5","article-title":"The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"D\u00f6rner","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/art.42485","article-title":"Lupus interference with B cell tolerance across the developmental continuum","volume":"75","author":"Pemberton","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of systemic lupus erythematosus","volume":"16","author":"Pan","year":"2020","journal-title":"World J Pediatr"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2020.4698","article-title":"Overexpression of Fc\u03b3RIIB regulates downstream protein phosphorylation and suppresses B cell activation to ameliorate systemic lupus erythematosus","volume":"46","author":"Sheng","year":"2020","journal-title":"Int J Mol Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061446","article-title":"Persistent expression of autoantibodies in SLE patients in remission","volume":"203","author":"Yurasov","year":"2006","journal-title":"J Exp Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e157250","DOI":"10.1172\/JCI157250","article-title":"Fc\u03b3RIIB regulates autoantibody responses by limiting marginal zone B cell activation","volume":"132","author":"Barlev","year":"2022","journal-title":"J Clin Invest"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02136","article-title":"Identification and characterization of post-activated B cells in systemic autoimmune diseases","volume":"10","author":"Wei\u00dfenberg","year":"2019","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2016.00022","article-title":"The effect of BAFF inhibition on autoreactive B-cell selection in murine systemic lupus erythematosus","volume":"22","author":"Boneparth","year":"2016","journal-title":"Mol Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1159\/000527213","article-title":"Aberrant B-cell activation in systemic lupus erythematosus","volume":"8","author":"Kang","year":"2022","journal-title":"Kidney Dis (Basel)"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1038\/s41467-024-48620-7","article-title":"The chromatin landscape of pathogenic transcriptional cell states in rheumatoid arthritis","volume":"15","author":"Weinand","year":"2024","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00933-7","article-title":"Epigenetic regulation of B cells and its role in autoimmune pathogenesis","volume":"19","author":"Xiao","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01486","article-title":"Repertoire analysis of B-cells located in striated ducts of salivary glands of patients with sj\u00f6gren\u2019s syndrome","volume":"11","author":"Visser","year":"2020","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098385","article-title":"B-cell receptor signaling is thought to be a bridge between primary sjogren syndrome and diffuse large B-cell lymphoma","volume":"24","author":"Mohammadnezhad","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","first-page":"117514","DOI":"10.1016\/j.bmc.2023.117514","article-title":"Review and prospects of targeted therapies for spleen tyrosine kinase (SYK)","volume":"96","author":"Wang","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial-immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54686-0","article-title":"Molecular and spatial analysis of tertiary lymphoid structures in Sjogren\u2019s syndrome","volume":"16","author":"Nayar","year":"2025","journal-title":"Nat Commun"},{"key":"B105","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13075-024-03283-z","article-title":"B cell receptor repertoire analysis in primary Sjogren\u2019s syndrome salivary glands identifies repertoire features associated with clinical activity","volume":"26","author":"Chang","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.684999","article-title":"The multiple roles of B cells in the pathogenesis of sj\u00f6gren\u2019s syndrome","volume":"12","author":"Du","year":"2021","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065656","article-title":"Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sj\u00f6gren's syndrome and systemic lupus erythematosus","volume":"66","author":"Sellam","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B108","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1172\/JCI14121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sj\u00f6gren\u2019s syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"key":"B109","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12865-020-00351-2","article-title":"A regulatory role for CD72 expression on B cells and increased soluble CD72 in primary Sjogren\u2019s syndrome","volume":"21","author":"Shen","year":"2020","journal-title":"BMC Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0227-z","article-title":"IL-10-producing regulatory B cells restrain the T follicular helper cell response in primary Sj\u00f6gren's syndrome","volume":"16","author":"Lin","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdsr.2019.09.006","article-title":"B cell dysregulation in primary Sj\u00f6gren\u2019s syndrome: A review","volume":"55","author":"Ibrahem","year":"2019","journal-title":"Jpn Dent Sci Rev"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.03.034","article-title":"De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease","volume":"134","author":"Mattoo","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0500-7","article-title":"IgG4-related disease: an update on pathophysiology and implications for clinical care","volume":"16","author":"Perugino","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205233","article-title":"Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations","volume":"74","author":"Wallace","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e167602","DOI":"10.1172\/jci.insight.167602","article-title":"Single-cell transcriptome analysis and protein profiling reveal broad immune system activation in IgG4-related disease","volume":"8","author":"Lu","year":"2023","journal-title":"JCI Insight"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-335375","article-title":"The dual role of IgG4 in immunity: bridging pathophysiology and therapeutic applications","volume":"74","author":"Piseddu","year":"2025","journal-title":"Gut"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab","volume":"367","author":"Roug\u00e9","year":"2020","journal-title":"Science"},{"key":"B118","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jaci.2019.07.004","article-title":"B lymphocytes directly contribute to tissue fibrosis in patients with IgG(4)-related disease","volume":"145","author":"Della-Torre","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1584107","article-title":"IgG4-related disease - focus on digestive system involvement","volume":"16","author":"Motor","year":"2025","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102944","article-title":"The landscape of T and B lymphocytes interaction and synergistic effects of Th1 and Th2 type response in the involved tissue of IgG4-RD revealed by single cell transcriptome analysis","volume":"133","author":"Cai","year":"2022","journal-title":"J Autoimmun"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-014-0431-y","article-title":"B cell-mediated pathogenesis of ANCA-mediated vasculitis","volume":"36","author":"Jennette","year":"2014","journal-title":"Semin Immunopathol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/s41467-025-56786-x","article-title":"Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"16","author":"Wortel","year":"2025","journal-title":"Nat Commun"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e150999","DOI":"10.1172\/jci.insight.150999","article-title":"Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis","volume":"6","author":"Berti","year":"2021","journal-title":"JCI Insight"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071446","article-title":"ANCA-associated vasculitis: an update","volume":"10","author":"Almaani","year":"2021","journal-title":"J Clin Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010387","article-title":"B lineage cells in ANCA-associated vasculitis","volume":"23","author":"Merino-Vico","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B127","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/j.akdh.2024.04.005","article-title":"ANCA-associated vasculitis","volume":"31","author":"Sharma","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"B128","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/ar2923","article-title":"T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells","volume":"12","author":"Wilde","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B129","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e70262","DOI":"10.1002\/mco2.70262","article-title":"Autoimmune diseases: molecular pathogenesis and therapeutic targets","volume":"6","author":"Song","year":"2025","journal-title":"MedComm (2020)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.668131","article-title":"Targeting bruton\u2019s tyrosine kinase in inflammatory and autoimmune pathologies","volume":"9","author":"Neys","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01592-0","article-title":"Bruton\u2019s tyrosine kinase inhibition as an emerging therapy in systemic autoimmune disease","volume":"81","author":"Neys","year":"2021","journal-title":"Drugs"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1454747","article-title":"Cutting-edge approaches to B-cell depletion in autoimmune diseases","volume":"15","author":"Robinson","year":"2024","journal-title":"Front Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton\u2019s tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"key":"B136","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s42358-024-00401-y","article-title":"Targeting Bruton\u2019s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments","volume":"64","author":"Tavakoli","year":"2024","journal-title":"Adv Rheumatol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102807","article-title":"Bruton\u2019s kinase inhibitors for the treatment of immunological diseases: current status and perspectives","volume":"11","author":"Robak","year":"2022","journal-title":"J Clin Med"},{"key":"B138","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","article-title":"BTK inhibitors: past, present, and future","volume":"45","author":"Cool","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026672","article-title":"Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors","volume":"145","author":"Tam","year":"2025","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0409","article-title":"New means and challenges in the targeting of BTK","volume":"30","author":"Nawaratne","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-7058001\/v1","article-title":"Orelabrutinib, an irreversible inhibitor of Bruton tyrosine kinase, for the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, phase Ib IIa study","author":"Li","year":"2025","journal-title":"Research Square"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/acr2.11511","article-title":"Efficacy and safety of the bruton\u2019s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial","volume":"5","author":"Wallace","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/S2665-9913(23)00089-9","article-title":"Evaluation of BMS-986142, a reversible Bruton\u2019s tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study","volume":"5","author":"Conaghan","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689472","article-title":"Resistance mutations to BTK inhibitors originate from the NF-\u03baB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway","volume":"12","author":"Smith","year":"2021","journal-title":"Front Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720704","article-title":"Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice","volume":"11","author":"O\u2019Brien","year":"2021","journal-title":"Front Oncol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e3294","DOI":"10.1002\/hon.3294","article-title":"Strategies for overcoming resistance to Bruton\u2019s tyrosine kinase inhibitor zanubrutinib","volume":"42","author":"Dost\u00e1lov\u00e1","year":"2024","journal-title":"Hematol Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217919","article-title":"Discovery of tricyclic pyranochromenone as novel bruton\u2019s tyrosine kinase inhibitors with in vivo antirheumatic activity","volume":"21","author":"Cho","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2016.09.003","article-title":"Trikatu, an herbal compound ameliorates rheumatoid arthritis by the suppression of inflammatory immune responses in rats with adjuvant-induced arthritis and on cultured fibroblast like synoviocytes via the inhibition of the NF\u03baB signaling pathway","volume":"258","author":"Doss","year":"2016","journal-title":"Chem Biol Interact"},{"key":"B152","doi-asserted-by":"publisher","first-page":"13612","DOI":"10.1038\/s41598-023-37729-2","article-title":"Phytochemical mediated modulation of COX-3 and NF\u03baB for the management and treatment of arthritis","volume":"13","author":"Biswas","year":"2023","journal-title":"Sci Rep"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00078","article-title":"Targeting syk in autoimmune rheumatic diseases","volume":"7","author":"Deng","year":"2016","journal-title":"Front Immunol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00281-017-0623-3","article-title":"Future therapeutic targets in rheumatoid arthritis","volume":"39","author":"Cheung","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2177\/jsci.35.56","article-title":"Involvement of Syk in pathology of systemic autoimmune disease","volume":"35","author":"Iwata","year":"2012","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1279155","article-title":"The selective inhibition of the Syk tyrosine kinase ameliorates experimental autoimmune arthritis","volume":"14","author":"K\u00e1poszt\u00e1s","year":"2023","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/ar3198","article-title":"Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases","volume":"12","author":"Pamuk","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"e20191336","DOI":"10.1084\/jem.20191336","article-title":"Activated PI3K\u03b4 breaches multiple B cell tolerance checkpoints and causes autoantibody production","volume":"217","author":"Lau","year":"2020","journal-title":"J Exp Med"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1337436","article-title":"Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome","volume":"15","author":"De","year":"2024","journal-title":"Front Pharmacol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/yagocb","article-title":"Selection of study endpoints and patients for clinical trials in primary Sj\u00f6gren\u2019s syndrome","volume":"40","author":"Arends","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead096","article-title":"Identification of new candidate drugs for primary Sj\u00f6gren\u2019s syndrome using a drug repurposing transcriptomic approach","volume":"62","author":"Felten","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1115244","article-title":"Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus","volume":"14","author":"Olayinka-Adefemi","year":"2023","journal-title":"Front Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140238","article-title":"A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-\u03b1 antagonist","volume":"41","author":"Genovese","year":"2014","journal-title":"J Rheumatol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205361","article-title":"OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy","volume":"74","author":"Taylor","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1002\/art.23992","article-title":"Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1039\/d0ra08769f","article-title":"Characterizing the structure-activity relationships of natural products, tanshinones, reveals their mode of action in inhibiting spleen tyrosine kinase","volume":"11","author":"Tung","year":"2021","journal-title":"RSC Adv"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S475959","article-title":"Sinomenine alleviates rheumatoid arthritis by suppressing the PI3K-akt signaling pathway, as demonstrated through network pharmacology, molecular docking, and experimental validation","volume":"18","author":"Liu","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237537","article-title":"Rituximab inhibits B-cell receptor signaling","volume":"115","author":"Kheirallah","year":"2010","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104708","article-title":"IgG4-related disease","volume":"9","author":"Mahajan","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1002\/art.41773","article-title":"2021 american college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"e163030","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of B cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab","volume":"367","author":"Roug\u00e9","year":"2020","journal-title":"Science"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B179","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of igG4-related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: A double-blind, randomized, placebo-controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1119510","article-title":"Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"14","author":"Dere","year":"2023","journal-title":"Front Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1235440","article-title":"Advances in natural products and antibody drugs for SLE: new therapeutic ideas","volume":"14","author":"Han","year":"2023","journal-title":"Front Pharmacol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: A regulator of innate and adaptive B cell responses and autoimmunity","volume":"9","author":"Clark","year":"2018","journal-title":"Front Immunol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0081-9","article-title":"Targeting co-stimulatory molecules in autoimmune disease","volume":"19","author":"Edner","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.539797","article-title":"A comprehensive review of biological agents for lupus: beyond single target","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1002\/art.40479","article-title":"Brief report: A randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis","volume":"70","author":"Cheng","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: A phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00256","article-title":"Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell Malignancies","volume":"3","author":"Puri","year":"2012","journal-title":"Front Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18773","article-title":"B cells and antibodies in refractory immune thrombocytopenia","volume":"203","author":"Roeser","year":"2023","journal-title":"Br J Haematol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"e032569","DOI":"10.1136\/bmjopen-2019-032569","article-title":"Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial","volume":"9","author":"Jones","year":"2019","journal-title":"BMJ Open"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1501019","article-title":"A comprehensive review of natural products in rheumatoid arthritis: therapeutic potential and mechanisms","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05417-z","article-title":"Efficacy and safety of curcumin in maintaining remission during disease-modifying antirheumatic drug withdrawal in rheumatoid arthritis at 52 weeks: a phase III double-blind, randomized placebo-controlled trial","volume":"43","author":"Bhat","year":"2023","journal-title":"Rheumatol Int"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.3390\/ph14040309","article-title":"The immunomodulatory and anti-inflammatory effect of curcumin on immune cell populations, cytokines, and in vivo models of rheumatoid arthritis","volume":"14","author":"Makuch","year":"2021","journal-title":"Pharm (Basel)"},{"key":"B202","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12906-021-03302-5","article-title":"Therapeutic effect of various ginsenosides on rheumatoid arthritis","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Complement Med Ther"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1502298","article-title":"The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment","volume":"15","author":"Guo","year":"2024","journal-title":"Front Pharmacol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03899-x","article-title":"Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Wang","year":"2025","journal-title":"Nat Med"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-024-01068-2","article-title":"Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis","volume":"35","author":"Li","year":"2025","journal-title":"Cell Res"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01880-6","article-title":"The promise of precision medicine in rheumatology","volume":"28","author":"Guthridge","year":"2022","journal-title":"Nat Med"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1103690","article-title":"Application of single-cell RNA sequencing methods to develop B cell targeted treatments for autoimmunity","volume":"14","author":"Nicholas","year":"2023","journal-title":"Front Immunol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"eabf1970","DOI":"10.1126\/science.abf1970","article-title":"Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus","volume":"376","author":"Perez","year":"2022","journal-title":"Science"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-02019-8","article-title":"Single-cell RNA sequencing of peripheral blood links cell-type-specific regulation of splicing to autoimmune and inflammatory diseases","volume":"56","author":"Tian","year":"2024","journal-title":"Nat Genet"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3390\/cells14070539","article-title":"Decoding B cells in autoimmune diseases through scRNA + BCR-seq: current knowledge and future directions","volume":"14","author":"Quan","year":"2025","journal-title":"Cells"},{"key":"B212","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s42003-022-03050-3","article-title":"Three-dimensional spatial transcriptomics uncovers cell type localizations in the human rheumatoid arthritis synovium","volume":"5","author":"Vickovic","year":"2022","journal-title":"Commun Biol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1038\/s41598-022-15293-5","article-title":"Integrated single cell and spatial transcriptomics reveal autoreactive differentiated B cells in joints of early rheumatoid arthritis","volume":"12","author":"Hardt","year":"2022","journal-title":"Sci Rep"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-023-01767-3","article-title":"Spatial proteomics landscape and immune signature analysis of renal sample of lupus nephritis based on laser-captured microsection","volume":"72","author":"Zheng","year":"2023","journal-title":"Inflammation Res"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2024.102021","article-title":"Novel biomarkers in RA: Implication for diagnosis, prognosis, and personalised treatment","volume":"39","author":"Neto","year":"2025","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179534","article-title":"Title current status of the search for biomarkers for optimal therapeutic drug selection for patients with rheumatoid arthritis","volume":"22","author":"Tsuchiya","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-021-00800-3","article-title":"Orchestrated modulation of rheumatoid arthritis via crosstalking intracellular signaling pathways","volume":"29","author":"Ibrahim","year":"2021","journal-title":"Inflammopharmacology"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.607725","article-title":"JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis","volume":"7","author":"Moura","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B220","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13075-025-03564-1","article-title":"CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future","volume":"27","author":"Jouret","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheumatol Int"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00786-4","article-title":"From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis","volume":"18","author":"Scherer","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"102887","DOI":"10.1016\/j.jaut.2022.102887","article-title":"Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment","volume":"132","author":"Jiang","year":"2022","journal-title":"J Autoimmun"},{"key":"B225","doi-asserted-by":"publisher","first-page":"117018","DOI":"10.1016\/j.bcp.2025.117018","article-title":"B cell-targeted therapies in systemic lupus erythematosus: Current status and perspectives","volume":"239","author":"Chen","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01135-3","article-title":"Update on the pathophysiology and treatment of primary Sj\u00f6gren syndrome","volume":"20","author":"Baldini","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1377055","article-title":"Emerging biologic frontiers for Sjogren\u2019s syndrome: Unveiling novel approaches with emphasis on extra glandular pathology","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"B228","doi-asserted-by":"publisher","first-page":"e1477","DOI":"10.1002\/cti2.1477","article-title":"The spectrum of B cells in the pathogenesis, diagnosis and therapeutic applications of immunoglobulin G4-related disease","volume":"12","author":"Hao","year":"2023","journal-title":"Clin Transl Immunol"},{"key":"B229","doi-asserted-by":"publisher","first-page":"S267","DOI":"10.37765\/ajmc.2021.88746","article-title":"Antineutrophil cytoplasmic antibody (ANCA) vasculitis: pathophysiology, diagnosis, and the evolving treatment landscape","volume":"27","author":"Koening","year":"2021","journal-title":"Am J Manag Care"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: A randomized, double-blind, phase II trial (ANDES study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B231","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bcp.12048","article-title":"Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies","volume":"76","author":"Baluom","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103719","article-title":"FcRn inhibitors: Transformative advances and significant impacts on IgG-mediated autoimmune diseases","volume":"24","author":"Zhu","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1002\/art.41812","article-title":"Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases","volume":"73","author":"Orvain","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01430-8","article-title":"Efficacy and safety of nipocalimab in patients with moderate-to-severe Sj\u00f6gren\u2019s disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial","volume":"406","author":"Noaiseh","year":"2025","journal-title":"Lancet"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B238","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100749","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","volume":"6","author":"Wang","year":"2025","journal-title":"Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:00:02Z","timestamp":1772607602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":239,"alternative-id":["10.3389\/fimmu.2026.1750557"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1750557","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1750557"}}